To investigate the impact of CYP2D6 and CYP2C19 polymorphisms in predicting tamoxifen efficacy and clinical outcomes in Thai breast cancer patients. Methods: Polymorphisms of CYP2D6 and CYP2C19 were genotyped by the AmpliChip™ CYP450 Test (Roche Molecular Diagnostics, Branchburg, NJ, USA) for 57 patients, who were matched as recurrent versus non-recurrent breast cancers (n = 33 versus n = 24, respectively, with a 5-year follow-up). Results: Based on the genotype data, five CYP2D6 predicted phenotype groups were identified in this study including homozygous extensive metabolizer (13 of , and homozygous poor metabolizer (3 of 57, 5.30%). The CYP2D6 variant alleles were *10 (52 of 114, 45.60%), *5 (5 of 114, 4.40%), *41 (2 of 114, 1.80%), *4 (1 of 114, 0.90%), and *36 (1 of 114, 0.90%); the CYP2C19 variant alleles were *2 (27 of 114, 23.70%) and *3 (6 of 114, 5.30%). Kaplan-Meier estimates showed significantly shorter disease-free survival in patients with homozygous TT when compared to those with heterozygous CT or homozygous CC at nucleotides 100C.T and 1039C.T (CYP2D6*10) post-menopausal (log-rank test; P = 0.046). They also had increased risk of recurrence, but no statistically significant association was observed (hazard ratio 3.48; 95% confidence interval 0.86-14.07; P = 0.080).
Introduction
Tamoxifen is the most commonly prescribed and widely used treatment and adjuvant therapy drug for the prevention of estrogen receptor/progesterone receptor-sensitive breast cancers in pre-and post-menopausal women. 1, 2 However, approximately 30%-50% of estrogen-positive breast cancer patients have recurrence of the disease and do not respond to tamoxifen treatment.
Polymorphisms in CYP2D6 and CYP2C19 are clinically important in the metabolism of drugs, as certain allele variants demonstrate either altered activity or nonfunctional enzyme activity with the consequence of 4-hydroxy tamoxifen and endoxifen plasma concentrations. 4 Several studies have discovered the association between CYP2D6 and CYP2C19 polymorphisms and plasma concentrations of active metabolites as well as the clinical outcome of breast cancer patients receiving tamoxifen. 5, 6 It has been reported that European breast cancer patients who receive tamoxifen and are homozygous for CYP2D6*4, thus a poor CYP2D6 metabolizer, have a significantly lower level of endoxifen plasma concentration when compared with homozygous wild type CYP2D6*1.
7-9 CYP2D6*10 (100C.T) is the most common intermediate metabolizer allele in the Asian population, which has an allele frequency of approximately 40%-70%. In contrast, Caucasians and African Americans were reported as having approximately a 2%-5% and 3%-8% allele frequency, respectively. [10] [11] [12] The CYP2D6*10 homozygous variant genotype could affect the efficacy of tamoxifen, and it is associated with significantly lower plasma concentrations of 4-hydroxy tamoxifen when compared with the homozygous wild type genotype. Also, it was found that breast cancer patients with the CYP2D6*10 homozygous variant genotype had a significantly worse disease-free survival (DFS) than those with heterozygous (CT) or homozygous wild type genotype. [13] [14] [15] Lim et al performed modeling analysis to investigate the influence of CYP2D6, genotype CYP3A5, CYP2C9, and CYP2C19 polymorphisms on tamoxifen pharmacokinetics and found that CYP2D6*5/*10 and *10/*10 were significantly associated with lower concentrations of endoxifen and N-desmethyl tamoxifen. 16 The CYP2C19 gene has two major poor metabolizer (PM) alleles that result in deficiency of the enzyme. However, information is limited on the possibility of the CYP2C19 genotype affecting the efficacy of tamoxifen, but the result from van Schaik et al demonstrated that CYP2C19 is associated with increased survival in breast cancer patients using tamoxifen. 17 Therefore, this study aimed to identify the polymorphisms in CYP2D6 and CYP2C19 in patients with breast cancer and to investigate the impact of genetic polymorphisms on disease recurrence in patients who received adjuvant tamoxifen.
Material and methods

Clinical subjects
Fifty-seven participants in this retrospective study were recruited from a primary recurrent and non-recurrent breast cancer population enrolled between February 1997 and January 2008 at the Department of Medicine, Ramathibodi Hospital in Bangkok, Thailand. All 57 patients were assigned randomly to receive 20 mg/day adjuvant tamoxifen for 5 years. This study was designed for 33 breast cancer recurrence and 24 breast cancer non-recurrence. The two groups were matched by the characteristics of the patients (Table 1) . Patients receiving selective serotonin reuptake inhibitors were excluded in the post hoc analyses. Written informed consent forms were obtained from all patients. The study was approved by the Ramathibodi Hospital Ethics Committee.
Patient characteristics
The use of adjuvant tamoxifen was similar in the two groups (cases and controls) ( Table 1 ). The mean age of the subjects was 48.9 ± 10.6 years. The median follow-up time of the case and control group was 93.5 months (range 59.0-172.0) and 22.0 months (range 2.0-62.0), respectively. The median follow-up time was 48.0 months (range 2.0-172.0). The number of pre-and post-menopausal patients was 38 and 19, respectively. All patients were estrogen receptor-positive except for one patient, who was estrogen receptor-negative but progesterone receptor-positive. Among the 33 patients with breast cancer recurrence, 6.06% (2/33) were human epidermal growth factor receptor-2 (Her-2)-positive and 60.60% (20/33) were of unknown status. Twenty-five (43.80%; 25/57) patients had positive axillary lymph nodes. Most patients were treated with a modified radical mastectomy. The adjuvant chemotherapy comprised cyclophosphamide, intravenous methotrexate, and 5-fluorouracil, and Adriamycin ® -based and Adriamycin-taxane-based regimens. Three patients in this study did not receive adjuvant chemotherapy, despite their eligibility for treatment, because they had positive lymph node (N1) axillaries (two patients in the control arm and one patient in the case arm, respectively). There was no significant difference in patient characteristics between non-recurrent and recurrent breast cancers ( Table 1) .
Analysis of polymorphisms in CYP2D6 and CYP2C19
Genomic DNA was extracted from ethylenediaminetetraacetic acid blood and isolated by the salting out procedure. 17 The microarray technique (AmpliChip™ CYP450 Test; Roche Molecular Diagnostics, Branchburg, NJ, USA) was used for detection of polymorphisms in CYP2D6 and CYP2C19 according to the manufacturer's instructions. 
Results
Allele frequencies of the CYP2D6 and CYP2C19
The polymorphisms observed in CYP2D6 and CYP2C19 were in Hardy-Weinberg equilibrium and they matched those in a previous report on Asian populations. Table 2 shows the frequencies of CYP2D6 alleles among different ethnic groups. The CYP2D6*10 and CYP2D6*5 (gene deletion) alleles were the most variant and nonfunctional, respectively, in this study, with variance and allele frequency of 45.6% and 4.40%, respectively. Rare variant alleles found that CYP2D6*36 and *41 had a frequency of 0.90% and 1.80%, respectively. The results showed that the CYP2D6*4 allele with a frequency of 0.90% was characterized by a 1846G.A mutation. The frequencies of CYP2C19 alleles are shown in Table 2 . The CYP2C19*2 allele was the most common variant found in this study at 23.70%. There were no significant differences in allelic frequencies of CYP2D6 and CYP2C19 between recurrent and non-recurrent breast cancers (Table S1 ).
Frequencies of the genotype and predicted phenotype of CYP2D6 and CYP2C19
Most of the CYP2D6 genotypes presented with heterozygous and homozygous intermediate metabolizer alleles. For example, CYP2D6*1/*10 and *10/*10 had allele frequencies of 28.10% (16/57) and 22.80% (13/57), respectively. Allele frequencies of the CYP2D6 genotypes were 15.70% for CY2D6*1/*1 (9/57), 3.50% for *1/*2 (2/57), 3.50% for *1/*5 (2/57), 1.80% for *1/*36 (1/57), 1.80% for *1/*41 (1/57), 3.50% for *2/*2 (2/57), 1.80% for *2/*4 (1/57), 7.00% for *2/*10 (4/57), 5.20% for *10/*5 (3/57), 1.80% for *10/*14B (1/57), 1.80% for *10/*35 (1/57), and 1.80% for *10/*41 (1/57) (Table S2) . Additionally, no homozygous PM or multiple copy (ultra-rapid metabolizer) of CYP2D6 alleles were observed in this study (Table 3) .
Frequency of the homozygous CYP2C19*1 and homozygous PM allele of the CYP2C19 genotype was 47.40% and 5.30% for *1/*1 (27/57) and *2/*2 (3/57), respectively. Frequency of the remaining CYP2C19 genotypes was 36.80% and 10.50% for *1/*2 (21/57) and *1/*3 (6/57), respectively (Table S2 ). In addition, Tables 3, S2 , and S3 shows no significant difference in the distribution of CYP2D6 and CYP2C19 genotypes and predicted phenotypes between recurrent and non-recurrent breast cancers.
CYP2D6 and CYP2C19 polymorphisms and breast cancer recurrence
The time it took for the patients to develop breast cancer recurrence was evaluated using Kaplan-Meier analysis. Kaplan-Meier estimates showed significantly shorter DFS (Figure 1 ) in patients with homozygous TT when compared to those with heterozygous CT or homozygous CC at nucleotides 100C.T and 1039C.T (CYP2D6*10) in post-menopausal women (log-rank test; P = 0.046 and submit your manuscript | www.dovepress.com Dovepress Dovepress P = 0.046), in which two single nucleotide polymorphisms were in linkage disequilibrium. In addition, patients with CYP2D6*10/*10 followed a different trend for DFS when compared to heterozygous CYP2D6*10 and homozygous wild type (CYP2D6 Wt/Wt) in post-menopausal women, but there was no statistical significance (P = 0.087).
Finally, no statistically significant difference in DFS was detectable in other nucleotides or genotypes of CYP2D6 and CYP2C19 (Tables S4 and S5) .
Risk estimation between genotypes of CYP2D6 and CYP2C19
Patients with heterozygous GA at nucleotide 1846G.A (CYP2D6*4) showed an increased risk of recurrence, but no overall statistically significant difference was observed in pre-menopausal patients (HR 5.82; 95% confidence interval [CI] 0.74-46.02; P = 0.094 and HR 5.84; 95% CI 0.70-48.55; P = 0.102). Overall, post-menopausal patients with homozygous TT at nucleotide 100C.T and 1039C.T (CYP2D6*10) tended to have increased risk of recurrence, but no statistically significant association was observed. In contrast, pre-menopausal patients with homozygous TT at nucleotides 100C.T and 1039C.T tended to have decreased risk of recurrence, but no significant association was observed (Table S6 ). On the other hand, the results showed that premenopausal patients with heterozygous GC at nucleotide 4180G.C had decreased risk of developing recurrence when compared to patients with homozygous GG (HR 0.48; 95% CI 0.20-1.15; P = 0.099). Table 4 shows that the genotype 
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of CYP2D6 and CYP2C19 had increased risk of developing recurrence, but no statistically significant association was observed.
Discussion
This study aimed to investigate the association between CYP2D6 and CYP2C19 polymorphisms and breast cancer outcomes in Thai female breast cancer patients treated with tamoxifen. The characteristics of breast cancer patients may affect the clinical outcome. Overall, the presence of variant CYP2D6 and CYP2C19 alleles had no significant difference in DFS between recurrent and non-recurrent breast cancers. However, Kaplan-Meier estimates showed a signif icant difference in DFS in patients with homozygous variant (TT) when compared with heterozygous variant (CT) or homozygous wild type (CC) at nucleotides 100C.T and 1039C.T (CYP2D6*10) in post-menopausal patients (log-rank test P = 0.046 and P = 0.046), in which two single nucleotide polymorphisms were associated with linkage disequilibrium.
Previous studies investigated the association between polymorphisms in CYP2D6 and tamoxifen efficacy and clinical outcomes in patients receiving adjuvant tamoxifen. 14, 15 Goetz et al initially reported that breast cancer patients with decreased CYP2D6 metabolism had a significantly shorter recurrence time (HR 1.91; 95% CI 1.05-3.45; P = 0.034) and worse relapse-free survival (HR 1.74; 95% CI 1.10-2.74; P = 0.017) when compared to patients with extensive CYP2D6 metabolism. Patients with the PM phenotype (CYP2D6*4/*4) had a significantly higher risk of breast cancer relapse approximately three times that of patients with extensive metabolizers (CYP2D6*1/*1 and *1/*4) (HR 3.12; P = 0.007). 22 Xu et al showed that patients with the CYP2D6*10 homozygous TT genotype had significantly worse DFS than those with the heterozygous CT and homozygous CC genotype (HR 4.7; 95% CI 1.1-20.0; P = 0.004). 13 Lim et al reported that patients with the CYP2D6*10/*10 genotype had a significantly higher risk of breast cancer relapse within 10 years after surgery when compared to those with other genotypes (time to progression 5.03 versus 21.8 months, P = 0.0032). 23 Kiyotani et al reported that patients with CYP2D6*10/*10 and CYP2D6*1/*10 showed significantly shorter recurrence-free survival when compared to those with CYP2D6*1/*1 (HR 9.52; 95% CI 2.79-32.45; P = 0.000036). 24 In contrast, previous studies from both European and Asian populations showed no significant association between polymorphisms in CYP2D6 and outcome of tamoxifen treatment. In the first, Okishiro et al reported no significantly different relapse-free survival rates between breast cancer patients with CYP2D6*10/*10 genotypes and those with CYP2D6*1/*1 or CYP2D6*1/*10 genotypes, nor was there a difference between patients with CYP2C19 PM genotypes (CYP2C19*2/*2, *2/*3, or *3/*3) and those with CYP2C19 extensive metabolizer genotypes (CYP2C19 *1/*1, *1/*2, or *1/*3). 25 Toyama et al demonstrated no significant correlation between patients with the CYP2D6*10/*10 genotype and survival time (DFS, distant DFS, breast cancer-specific survival, and overall survival) when compared to those with CYP2D6 *1/*1 and *1/*10 genotypes. 26 In contrast, a report from Sweden showed that patients with the CYP2D6*4/*4 genotype had significantly better DFS than those with heterozygous or homozygous CYP2D6*1 (P = 0.004 and P = 0.005, respectively). 27 The data in this study support the conclusion that CYP2D6 and CYP2C19 variants are not significantly associated with the clinical outcome in breast cancer patients taking adjuvant tamoxifen. Conversely, in a group of post-menopausal women, the polymorphisms in CYP2D6*10/*10 might be useful in predicting tamoxifen efficacy and clinical outcomes when compared to heterozygous CYP2D6*10 and homozygous wild type (CYP2D6 *1/*1).
However, this study had some limitations. Primarily, the retrospective nature of the study design is weak, which it shares with all other available studies. This retrospective method also lacks data correlation between polymorphisms in CYP2D6 and the plasma concentration of tamoxifen metabolites. While the small sample size and low number of PM phenotypes in this study may have given a low statistical power, all samples collected from the recruited were matched in a case-control manner.
It is possible that one or more of these variants are associated with a specific subgroup of breast cancer patients. The data in this study showed that the high frequency of CYP2D6*10 is similar to Asian populations reported previously, 9, 21 and only nine variations include gene deletion, gene conversion, 1584C.G, 100C.T, 1039C.T, 1661G.C, 1846G.A, 2850C.T, and 4180G.C. No homozygous CYP2D6 PM (CYP2D6*3, *4, and *5) or homozygous ultra-rapid metabolizers (CYP2D6*1XN, *2XN, and *35XN) in this study is due possibly to the small sample size.
Conclusion
The variant alleles of CYP2D6 and CYP2C19 genes in this study were not involved in tamoxifen efficacy. However, in the subgroup of post-menopausal women, the polymorphisms submit your manuscript | www.dovepress.com
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in CYP2D6 and CYP2C19 might be useful in predicting tamoxifen efficacy and clinical outcomes in breast cancer patients receiving adjuvant tamoxifen treatment. As the number of breast cancer patients was small in this study, results should be confirmed in a larger group of patients. 
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